According to an announcement made by Bayer HealthCare Pharmaceuticals, the Phase III trial of its investigational compound regorafenib (BAY 73-4506) to treat individuals with metastatic colorectal cancer (mCRC) whose disease progressed after approved standard treatments has reached its initial endpoint of statistically significant improvement in overall survival...
More...
More...